about
Impact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentA network map of Interleukin-10 signaling pathwayDiagnosis of systemic metastatic retinal lymphoma.Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas.Molecular pathology of primary intraocular lymphoma.Carcinogenicity testing of IL-10: principles and practicalities.Relationship between NADPH and Th1/Th2 ratio in patients with non-Hodgkin lymphoma who have been exposed to pesticides.Delayed infection, family size and malignant lymphomas.Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders.Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone useDistinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis.Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.Cancer Cytokines and the Relevance of 3D Cultures for Studying Those Implicated in Human Cancers.Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 transactivation through matrix attachment regions.IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.Role of Interleukin-10 Gene Promoter Region Polymorphism in the Development of Chronic Lymphoid Leukemia.Serum nm23-H1 protein as a prognostic factor in hematological malignancies.Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries?Syk inhibition with fostamatinib leads to transitional B lymphocyte depletionInterleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
P2860
Q26779947-BE51D346-280B-4F61-AB18-CBE42EF027D8Q28603589-12453061-7020-4141-95BA-BF9469297BCBQ33940200-17C3945B-D8EA-41A3-9408-07E04A16A42CQ34244468-EB23CD79-1E62-4651-B4E4-08097CFA537BQ34331092-075A9E5B-1B8B-4971-B7B0-232D4E9AFE72Q34880596-BC5C3EF9-7A8A-4DFC-9B13-5817D61C6AFDQ35284477-FC315397-12C9-4E73-B3A5-8E8F0F45471BQ35400803-E4D3AF47-E16D-4A1D-AC38-0A0D5A3A85C2Q35552189-4D22A869-F611-4EFF-B1B6-EBECB43B99A0Q36272592-D8FC16EC-8847-4FC6-AA68-4CB6CA5ED98CQ37306222-DD92DFEE-32FC-4A6C-8A01-BE1BD557D903Q37653084-29B04B24-3ECA-4701-9170-FCDF272FB89BQ38896751-24846C12-781A-4E5F-8844-B3DE884234A8Q38942281-12891586-E933-400C-A78E-078EBB58DE27Q39163607-2B5DB0A5-BAB7-4218-B72C-EB7806FDF148Q39257959-FEDCC180-8FF2-47DA-BF09-25464740F8F0Q39921861-FBBDB6CD-9011-4B0A-B98D-B4F5C57EB72AQ40041190-F778EE18-4B9C-4632-907C-FD9B69939ADFQ40237247-BABC2819-0E5C-4A5F-A8A0-6D144B568631Q40713872-35D69FC8-F0FD-41AF-9AB5-BA56572F4ACEQ41976089-B3EA0126-346C-42DA-9B12-2E5F8046F7DDQ42073989-1EA7359C-89DC-4DB6-AE19-E124DD4B4775Q53573964-AA8E5231-1DCA-48F8-A8FA-96B606BDD595
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Interleukin-10 in non-Hodgkin's lymphoma.
@en
type
label
Interleukin-10 in non-Hodgkin's lymphoma.
@en
prefLabel
Interleukin-10 in non-Hodgkin's lymphoma.
@en
P2860
P1433
P1476
Interleukin-10 in non-Hodgkin's lymphoma.
@en
P2093
P2860
P304
P356
10.3109/10428199709051774
P577
1997-07-01T00:00:00Z